Novartis Ag

Phares Pharmaceutical Research, N.v.

Pierre Fabre Medicament

Phares Pharmaceutical Research N.v. Et Al.

Novartis Pharma Gmbh

Medlite A/s

Biorelevant.com Ltd

Phares Drug Delivery Ag

Peter Van Hoogevest

Steve Leigh

Mathew Louis Steven Leigh

Jacques Quinton

Elie Leverd

John Afseth

Daniel Streich

Ketil Andre Hansen

Tore Fagerland

Elsa Kung

Mathew Leigh

Matthew Louis Steven Leigh

Mathew Louis Leigh

Henricus Tiemessen

There are described solid compositions or examining drug solubility comprising bile salts and phospholipids, optionally containing buffer components suitable for preparation of intestinal media that simulate the composition of the intestinal fluids in fasted and fed states.

Dissolution composition for examining drug solubility

The present invention relates to a pharmaceutical composition to be parenterally administered, including submicronic ester particles of docosahexaenoic acid, dispersed in an aqueous phase using a mixture of at least two surfactants selected from among a) at least one polyoxyethylene fatty acid ester and b) at least one phospholipid derivative. The present invention also relates to the method for preparing said pharmaceutical composition.

Pharmaceutical composition including a DHA ester to be administered parenterally

The present disclosure describes a method for the continuous dissolution of e.g. crystalline astaxanthin or canthaxanthin suspension in oil, by applying heat for a predetermined period using an in-line or optionally batch wise-process, followed by cooling the heated solution with an oil phase or heat exchanger. The resulting oil solution may be used as such or added directly to feed components which are turned into feed compositions by extrusion, compaction or granulation. Alternatively the oil solution is spray coated or directly loaded to extruded or compacted pellets and granulates. The disclosure avoids using formulated carotenoids prepared by known multi-step production methods requiring solvents, solvent removal, cooling and emulsification with an aqueous phase or precipitation and recovery steps. Thus the present invention is a more economical, efficient and environmentally friendly method to add nutrients and colorants to feed compositions instead of using colloid dispersed particulate hydrocolloid compositions.

Direct dissolution

Mixtures of specific crystal forms of astaxanthin and the individual crystal forms designated crystal Form I and II and disclosed together with methods for preparing said crystal Forms. Methods for preparing nutritional dosage forms including the disclosed astaxanthin crystal forms for the life science industry are also disclosed.

Crystal forms of astaxanthin

Pharmaceutical formulations comprising an epothilone in the form of an infusion concentrate or a lyophilised composition, and methods of administration of an epothilone in suitable form for parenteral administration.

Organic compounds

The invention is concerned with a parenteral formulation comprising a 5H-dibenz(b,f)azepine-5-carboxamide and an aqueous-based solvent. The parenteral formulation is useful in the treatment of seizures resulting from, e.g. epileptic attack.

Parenteral formulations comprising carbamazepine or its derivatives

Growing community of inventors

Bubendorf, Switzerland

Peter Van Hoogevest